Press release
Myopia Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approvals, Mechanism of Action, ROA, IND, NDA Approval and Companies by DelveInsight
Myopia Clinical Trials
(Albany, USA) "Myopia Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Myopia Therapeutics Market.
As per DelveInsight's assessment, globally, about 8+ key pharma and biotech companies are working on 10+ pipeline drugs in the Myopia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
The report provides a detailed description of the Myopia drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Myopia Clinical Trial Activities and Regulatory Developments in the domain @ Myopia Pipeline Outlook [https://www.delveinsight.com/report-store/myopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr]
Key Takeaways from the Myopia Pipeline Report
* DelveInsight's Myopia pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Myopia treatment.
* The leading Myopia Companies such as Sydnexis, Sunhawk Vision Biotech, Vyluma, Eyenovia, Cloudbreak Therapeutics, Stuart Therapeutics, and others.
* Promising Myopia Therapies such as SYD-101 Dose 1, Alleance, NVK-002 Concentration 1, QLM3004 Concentration 1, Atropine Sulfate 01, and others.
* In March 2025, Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Arise, a lens fitting system that uses intelligent, cloud-based technology to streamline the orthokeratology lens design process. Arise seamlessly syncs directly with topographers - diagnostic tools that capture 3-D images of the eye - to create precise lens designs in seconds to treat myopia. These lenses include the first orthokeratology lens design with toric peripheral curves* approved by the U.S. Food and Drug Administration to treat myopia overnight.
* In March 2025, Sydnexis, Inc. a pre-commercial stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for SYD-101 and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 23, 2025. If approved, SYD-101 would be the first and only pharmaceutical option for the treatment of progression of pediatric myopia in the United States.
* In January 2025, ZEISS Medical Technology announced today that the MEL Registered 90 received approval from the U.S. Food and Drug Administration (FDA), giving the excimer laser technology simultaneous approval for all three major indications, including myopia, hyperopia and mixed astigmatism (a condition where both hyperopic and myopic correction is required). The ZEISS MEL 90 fully integrates into the Corneal Refractive Workflow to offer U.S. surgeons a fast, reliable, and streamlined surgery experience, complementing the VISUMAX Registered 800 with SMILE Registered pro from ZEISS to help further broaden a surgeon's refractive business with improved patient attraction and positive clinical outcomes.
* July 2024:- Hoffmann-La Roche- This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in patients with myopic choroidal neovascularization (CNV). This non-inferiority study will compare 6.0 mg faricimab versus 0.5 mg ranibizumab administered at a pro-re-nata (PRN) dosing regimen after an initial active IVT treatment administration at randomization (Day 1).
* July 2024:- VIS Inc.- The goal of this clinical trial is to evaluate the safety and efficacy of using the VIS Opti-K System to enable monovision by providing temporary improvement in near vision through the treatment of the non-dominant eye of low myopic, emmetropic and low hyperopic presbyope subjects. The main questions it aims to answer are determining uncorrected near visual acuity at 40cm in the treated eye and subjective improvement as measured by the patient satisfaction questionnaire.
Myopia Pipeline Analysis
The report provides insights into:
* The report provides detailed insights into the key companies that are developing Myopia therapies.
* The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myopia treatment.
* It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* It navigates the emerging Myopia drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Myopia treatment market.
Learn More about the Clinical and Commercial Development Activities in the Myopia Therapeutics Domain @ Myopia Clinical Trials and Advancements [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr]
Myopia Therapeutics Analysis
Around 8+ prominent companies are actively engaged in the development of therapies for Myopia. Among these, Sydnexis stands out for advancing its Myopia drug candidates to the most advanced stage of clinical trials, specifically Phase III. This pivotal phase marks a critical milestone in the drug development journey, where the effectiveness and safety of the treatment are thoroughly evaluated in a larger patient population. Sydnexis's progress to Phase III underscores the potential significance of their therapeutic approach in addressing the challenges associated with Myopia, reflecting dedication and advancement within the field of ophthalmology and vision care.
Myopia Companies in the Therapeutics Market Include:
* Sydnexis
* Sunhawk Vision Biotech
* Vyluma
* Eyenovia
* Cloudbreak Therapeutics
* Stuart Therapeutics
And Many Others
Emerging and Marketed Myopia Therapies Covered in the Report Include:
* SYD-101 Dose 1
* Alleance
* NVK-002 Concentration 1
* QLM3004 Concentration 1
* Atropine Sulfate 01
* And Many Others
Get an in-depth Assessment of the Emerging Therapies and Myopia Companies Actively Working in the Market @ Myopia Medication and Manufacturers [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr]
The Myopia Pipeline report covers the Emerging Myopia Therapies under Different Phases of Clinical Development Like -
* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued and inactive candidates
Myopia Route of Administration
Myopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Myopia Molecule Type
Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Request for Sample PDF to Understand More About the Myopia Treatment Outlook and Future Perspectives @ Myopia Therapies and Drugs [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Myopia Current Treatment Patterns
4. Myopia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Myopia Late-Stage Products (Phase-III)
7. Myopia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Myopia Discontinued Products
13. Myopia Product Profiles
14. Myopia Companies
15. Myopia Drugs
16. Dormant and Discontinued Products
17. Myopia Unmet Needs
18. Myopia Future Perspectives
19. Myopia Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings @ https://www.delveinsight.com/sample-request/myopia-pipeline-insight [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr]
About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myopia-clinical-trials-analysis-2025-ema-pdma-fda-approvals-medication-therapies-nice-approvals-mechanism-of-action-roa-ind-nda-approval-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myopia Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approvals, Mechanism of Action, ROA, IND, NDA Approval and Companies by DelveInsight here
News-ID: 3986017 • Views: …
More Releases from ABNewswire
Top 6 Deck Builders In Kansas City For Stunning Outdoor Spaces
Outdoor living has evolved to become something more.
It is now a lifestyle choice.
Today's families seek spaces that harmonize with the natural world, yet remain as comfortable and well-designed as rooms in their homes. Patios and pergolas aren't an afterthought, but an absolute must that adds significant value to your property and makes everyday life better.
In areas with seasonal weather, where people can be outside for most of the year, homeowners…
Dash Capital Expands Zero Interest Business Loans in Detroit Following Unprecede …
Dash Capital's expansion in Detroit reflects strong demand from local businesses for flexible, fast funding solutions that support growth and operational needs across the Motor City's diverse economic landscape.
The Detroit business landscape continues to show remarkable resilience and growth potential, prompting Dash Capital to expand its funding programs in response to overwhelming demand from local entrepreneurs. This expansion comes at a time when Motor City businesses are actively seeking alternative…
Jacksonville Family Business Expands Concrete Washing Services Amid Growing Prop …
Nubirth Pressure Washing, a family-owned company serving Jacksonville since 2004, reflects the growing demand for specialized exterior property cleaning in Northeast Florida, offering comprehensive surface restoration services.
Jacksonville, FL - The Northeast Florida property maintenance industry has witnessed significant growth in specialized cleaning services as homeowners and businesses prioritize exterior property care. Local family-owned company Nubirth Pressure Washing [https://www.google.com/maps/place/Nubirth+Pressure+Washing/@30.3340387,-81.7122184,17z/data=!3m1!4b1!4m6!3m5!1s0x88e5b9c01d715555:0xd2c2470a4640f2be!8m2!3d30.3340387!4d-81.7122184!16s%2Fg%2F11vk2l_v57!5m1!1e3?entry=ttu&g_ep=EgoyMDI1MDgyNS4wIKXMDSoASAFQAw%3D%3D] represents this trend, having served the Jacksonville area since 2004 with comprehensive…
A-Class Moving & Storage Expands Direct Delivery Network, Positioning Miramar Mo …
A-Class Moving & Storage, based in Miramar, has expanded its direct delivery network across South Florida, strengthening its position as a leading moving company and reliable alternative to traditional van line brokers. The growth allows the family-owned business to serve more customers while preserving its personalized service standards.
A-Class Moving & Storage has announced a significant expansion of its direct delivery network throughout South Florida, establishing the business as a leading…
More Releases for Myopia
Myopia Control Lenses Market Forecast to Expand at 16.2% CAGR Amid Increasing Pe …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Myopia Control Lenses Market- (By Lens Type (Multifocal Lenses, Orthokeratology Lenses, Dual-Focus Lenses, Peripheral Defocus Lenses), By Age Group (Children, Adults), By Distribution Channel (Optometry Clinics, Optical Retail Stores, Online Retail)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic, the Global Myopia Control Lenses Market is valued…
Myopia Control Lenses Market Size to Grow with Rising Prevalence of Childhood My …
The latest Myopia Control Lenses Market research report offers crucial insights into how the industry is evolving, highlighting key drivers of growth and the main revenue streams expected between 2025 and 2032. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The Industry compass guiding business through the complexities of the market, presenting not only the current landscape but also the latest innovations shaping its…
Latest Trends In Myopia Treatment Devices Market
A cutting-edge solution to the problem of myopia or nearsightedness is a wearable gadget for myopia control.
These tools, which frequently come in the shape of smart glasses or specialised contact lenses, make use of cutting-edge technology to control and slow the growth of myopia.
Wearable myopia control devices offer a proactive method of maintaining eye health by utilising features like changeable focus, customised vision correction, and real-time monitoring.
Request…
Myopia Control Devices Market - Seeing Beyond Blur: Revolutionary Myopia Devices …
Newark, New Castle, USA: The "Myopia Control Devices Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Myopia Control Devices Market: https://www.growthplusreports.com/report/myopia-control-devices-market/7989
This latest report researches the industry structure,…
Myopia Control Devices Market - Unlocking the Future of Clear Sight: Myopia Cont …
Newark, New Castle, USA - new report, titled Myopia Control Devices Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Myopia Control Devices market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Myopia Control Devices market. The report offers an overview of…
The Myopia Market is expected to be driven by the factors such as the rising cas …
The Myopia market is expected to show positive growth, mainly attributed to the increased diagnosed prevalence and also, the launch of upcoming devices during the forecast period. Moreover, advances in disease mechanisms have yielded new diagnostic and treatment approaches, opening avenues to better treatment interventions.
The Myopia market report provides current treatment practices, emerging drugs, Myopia market share of the individual therapies, current and forecasted Myopia market Size from 2019 to…
